Ascelia Pharma: Investment Case
Today, we release an Investment Case on Ascelia Pharma AB that has their primary pipeline product, Orviglance - an imaging contrast agent for liver cancer patient with poor functioning kidneys – in phase 3. In the Investment Case we calculate the likelihood that the company gets Orviglance approved to be below 25 pct. according to the current market value of the company. From an investment perspective, Ascelia Pharma AB offers huge potential if Orviglance is approved and marketed later in 2023 as expected by the company.
#digitalir #Orviglance #Oncoral
HC Andersen Capital modtager betaling fra Ascelia Pharma AB for en Digital IR/Corporate Visibility abonnementsaftale. /Henrik Ekman kl. 16:20 24/3-2022
Ascelia Pharma
Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital. Ascelia Pharma is listed on Nasdaq Small Cap Stockholm with ticker ACE.
Read more on company page